Rangeley Capital bets on drugs and boxes
June 28, 2011
Suzy Kenly Waite
The New Canaan firm has generated fat returns wagering on a fat-killing drug.
In late 2007, Chris DeMuth believed there would be a tremendous uptick in mergers and acquisitions. To exploit the trend, he left his job as an event-driven analyst at Mangan & McColl Partners and launched Rangeley Capital in January 2008.
The story might have ended in misery, which stocks going every which way and mergers falling apart in the turmoil of Fall and Winter 2008, but Rangeley Capital survived, dropping 15% in 2008, but coming back stronger than most of its...
TAKE A FREE TRIAL
The full contents of this article are available to Absolute Return subscribers and trialists only.
To continue reading please, take a free trial, subscribe or log in.
Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.